For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220324:nRSX9194Fa&default-theme=true
RNS Number : 9194F N4 Pharma PLC 24 March 2022
24 March 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce that at its annual general meeting ("AGM"), held earlier
today, all resolutions were duly passed. The results of the proxy voting for
the AGM are set out below.
Resolution (*Special Resolution) Total Shares Voted Shares %
For Against For Against
1. To receive the annual report and audited accounts for the year ended 31 20,171,351 20,171,151 200 99.999 0.001
December 2021
2. To re-elect Nigel Theobald as a Director of the Company 20,195,551 20,026,641 168,910 99.164 0.836
3. To re-elect David Templeton as a Director of the Company 20,195,551 20,016,641 178,910 99.114 0.886
4. To re-appoint Saffery Champness LLP as auditor to the company and authorise 20,193,244 19,930,222 263,022 98.697 1.303
the directors to determine their remuneration
5. To authorise the Directors to allot shares 20,192,844 19,694,856 497,988 97.534 2.466
6*. To disapply pre-emption rights 20,190,444 19,928,374 262,070 98.702 1.298
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
IFC Advisory Limited Tel: +44 (0)20 3934 6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGBBGDXCDDDGDS